ASH 2021 | GRIFFIN: subgroup analysis of patients with multiple myeloma with high-risk cytogenetics
Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, outlines the results of a subgroup analysis of the GRIFFIN trial (NCT02874742) investigating the efficacy of the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (D-RVd) in patients with multiple myeloma with high-risk cytogenetics. Dr Voorhees explains that adding 1q21 gain to the high-risk markers defined by IMWG criteria increases the study’s power which allows determining whether daratumumab provides a significant benefit to this patient population. After incorporating patients with 1q21 gain to the subgroup analysis, the study reported a trend towards an improved progression-free survival (PFS) for high-risk patients treated with D-RVd compared to RVd alone. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Janssen: Other: Advisory Board; Novartis: Consultancy; Oncopeptides: Consultancy, Honoraria; TeneoBio: Other: Advisory Board; Adaptive Biotechnologies: Other: Advisory Board; BMS: Other: Advisory Board; GSK: Honoraria.
